| Medioni, Jacques |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
| Completed | 2 | 100 | Europe | Atezolizumab, Paclitaxel, Bevacizumab, Avastin | MedSIR, Hoffmann-La Roche | Metastatic Breast Cancer, Advanced Breast Cancer, Triple Negative Breast Cancer | 12/23 | 12/23 | | |
EMPRESS, NCT05659563: Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67≥10% |
|
|
| Recruiting | 2 | 92 | Europe | Giredestrant, GDC-9545, Tamoxifen, Nolvadex® or Soltamox® | MedSIR | Breast Cancer, Breast Cancer, Early-Onset | 11/24 | 12/24 | | |
| Active, not recruiting | 1/2 | 856 | Europe, Canada, Japan, US, RoW | LOXO-292, Selpercatinib, LY3527723 | Loxo Oncology, Inc., Eli Lilly and Company | Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor | 02/25 | 02/26 | | |
|
|
METex14, NCT04868877 / 2021-000203-20: Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination |
|
|
| Recruiting | 1/2 | 576 | Europe, US, RoW | MCLA-129, bispecific, Osimertinib, Tagrisso, Chemotherapy | Merus N.V. | Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer | 03/26 | 03/27 | | |
NCT04901806: Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors |
|
|
| Terminated | 1 | 29 | Europe, US, RoW | PBI-200 | Pyramid Biosciences | Solid Tumor, Adult, Brain Tumor, Primary, Desmoplastic Small Round Cell Tumor | 07/23 | 07/23 | | |
GARNET, NCT02715284: Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 740 | Europe, Canada, US, RoW | Dostarlimab | Tesaro, Inc. | Neoplasms | 05/26 | 10/27 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lee, Sang Il |
NCT05199441: Efficacy of Galeo® in Patients With Postprandial Distress Syndrome Subtype in Functional Dyspepsia |
|
|
| Completed | 4 | 226 | RoW | Dihydroxydibutylether group, Galeo® group, Control group placebo, Placebo | Pusan National University Yangsan Hospital | Dyspepsia | 07/23 | 07/23 | | |
NCT05701540: A Study to Evaluate the Efficacy and Safety of Tegoprazan in GERD Patients With Nighttime Heartburn |
|
|
| Recruiting | 4 | 338 | RoW | Tegoprazan, Esomeprazole | HK inno.N Corporation | Gastroesophageal Reflux Disease | 12/24 | 12/24 | | |
| Recruiting | 4 | 3944 | RoW | aspirin, clopidogrel, prasugrel, ticagrelor | Asan Medical Center | Coronary Artery Disease | 08/27 | 12/28 | | |
| Active, not recruiting | 3 | 104 | RoW | Autologous Chondrocyte Implantation (CartiLife®), CartiLife, Microfracture Surgery | Biosolution Co., Ltd. | Articular Cartilage Defect, Articular Cartilage Degeneration | 09/23 | 09/24 | | |
| Active, not recruiting | 3 | 404 | Europe, Canada, Japan, US, RoW | Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo | Chinook Therapeutics, Inc. | IgA Nephropathy, Immunoglobulin A Nephropathy | 12/26 | 12/26 | | |
NCT06466785: A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis |
|
|
| Recruiting | 3 | 429 | RoW | Efepoetin Alfa, GX-E4, Darbepoetin Alfa, Aranesp® | Genexine, Inc., PT Kalbe Genexine Biologics | Anemia of Chronic Kidney Disease | 12/26 | 09/27 | | |
| Active, not recruiting | 3 | 806 | Europe, Canada, Japan, US, RoW | Placebo, Mepolizumab | GlaxoSmithKline, PPD | Pulmonary Disease, Chronic Obstructive | 08/24 | 08/24 | | |
|
|
|
|
|
| Active, not recruiting | 3 | 597 | Europe, RoW | Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer | United Therapeutics | Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease | 07/25 | 07/25 | | |
ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities |
|
|
| Active, not recruiting | 3 | 3000 | Europe, Japan, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | Obesity, Overweight, Overweight or Obesity | 07/25 | 07/27 | | |
| Active, not recruiting | 3 | 2100 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Obesity, Overweight, Knee Pain Chronic, Knee Osteoarthritis, Obstructive Sleep Apnea | 04/26 | 05/26 | | |
NCT04969731: Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer |
|
|
| Recruiting | 3 | 408 | RoW | Immuncell-LC, Autologous activated T lymphocyte, Gemcitabine | GC Cell Corporation | Pancreatic Ductal Adenocarcinoma | 12/26 | 06/27 | | |
NCT06073132: An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS) |
|
|
| Recruiting | 2/3 | 80 | Europe, US, RoW | AC-203, Vehicle | TWi Biotechnology, Inc. | Generalized Epidermolysis Bullosa Simplex | 08/25 | 03/26 | | |
| Active, not recruiting | 2 | 103 | Europe, US, RoW | Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627 | Chinook Therapeutics, Inc. | IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease, Diabetic Nephropathy Type 2, Immunoglobulin A Nephropathy | 07/24 | 07/26 | | |
| Active, not recruiting | 2 | 129 | Europe, US, RoW | BBT-877, Placebo | Bridge Biotherapeutics, Inc. | Idiopathic Pulmonary Fibrosis | 01/25 | 09/25 | | |
|
|
NCT05944627: Evaluate Safety and Explore Efficacy of FURESTEM-OA Kit Inj. in Patients With Knee Osteoarthritis |
|
|
| Not yet recruiting | 1/2 | 68 | NA | FURESTEM-OA Kit Inj., Placebo | Kang Stem Biotech Co., Ltd. | Knee Osteoarthritis | 03/24 | 02/26 | | |
NCT05045534: A Study to Investigate the Safety, Tolerability and Pharmacokinetics of TB-840 in Healthy Subjects |
|
|
| Completed | 1 | 96 | RoW | Comparison of TB-840 treatment with Placebo, TB-840 | Therasid Bioscience | Healthy Volunteers | 08/22 | 12/22 | | |
NCT02601417: The Necessity of Bile Cultures in Patients With Acute Cholangitis |
|
|
| Active, not recruiting | N/A | 440 | RoW | Ignoring result of bile culture | Seoul National University Hospital | Acute Cholangitis | 03/24 | 07/24 | | |
NCT04810312: Combined Exercise and Nutrition Intervention for Spinal Sarcopenia |
|
|
| Not yet recruiting | N/A | 35 | NA | Combined exercise and nutrition intervention | Seoul National University Hospital | Sarcopenia | 03/22 | 05/22 | | |
NCT04416763: Diagnostic Value of Endoscopic Ultrasound Elastography and Contrast Enhanced Endoscopic Ultrasound for Differential Diagnosis of Gallbladder Polyp |
|
|
| Recruiting | N/A | 30 | RoW | | Seoul National University Hospital | Gallbladder Polyps or Masses Greater Than 8-10 mm in Size | 04/22 | 06/22 | | |
| Recruiting | N/A | 80 | RoW | early refeeding, delayed refeeding | Yonsei University | Post-ERCP Pancreatitis | 11/22 | 12/22 | | |
| Recruiting | N/A | 140 | RoW | Renal Denervation | Kalos Medical | Hypertension, Vascular Diseases, Cardiovascular Diseases | 07/23 | 04/24 | | |
NCT05220475: A Comparison of a Fully Covered Self-expandable Metal Stent With an External Anchoring Plastic Stent and Uncovered Stent |
|
|
| Recruiting | N/A | 108 | RoW | fully covered self-expandable metal stent with an anchoring external plastic stent, uncovered self-expandable metal stent | Seoul National University Hospital | Malignant Biliary Obstruction | 10/23 | 10/24 | | |
NCT05544825: Ice Plant (Mesembryanthemum Crystallinum) Extract in Patients With Impaired Fasting Glucose |
|
|
| Completed | N/A | 40 | RoW | Ice plant group, Placebo group | Pusan National University Yangsan Hospital | Impaired Fasting Glucose | 10/23 | 10/23 | | |
| Enrolling by invitation | N/A | 100 | RoW | BK329, Placebo | Pusan National University Yangsan Hospital | Obesity and Overweight | 12/24 | 12/24 | | |
NCT03775837: Effect of Panax Ginseng C.A. Mey Extract on Liver Function in Adults |
|
|
| Recruiting | N/A | 60 | RoW | Panax Ginseng C.A. Mey Extract group, Placebo group | Pusan National University Yangsan Hospital | Liver Diseases | 12/24 | 12/24 | | |
NCT04320199: Effect of Fermented Protaetia Brevitarsis Seulensis Powder on Alcohol-induced Liver Disease |
|
|
| Recruiting | N/A | 30 | RoW | Fermented Protaetia brevitarsis seulensis powder group, Placebo group | Pusan National University Yangsan Hospital | Alcoholic Liver Disease | 12/24 | 12/24 | | |
NCT06091033: Perceived Stress and Black Rice (Oryza Sativa L.) Extract Fermented With Lactobacillus |
|
|
| Completed | N/A | 80 | RoW | Fermented rice, placebo | Pusan National University Yangsan Hospital | Perceived Stress | 12/23 | 12/23 | | |
NCT05180136: Efficacy of Rice Bran Extract in Mildly to Moderately Depressed Adults |
|
|
| Completed | N/A | 100 | RoW | Rice bran extract group, Control group | Pusan National University Yangsan Hospital | Depression | 12/22 | 12/22 | | |
NCT05548842: The Combined Seed Extracts of Cassia Obtusifolia Linne and Foeniculum Vulgare Mill in Patients With Chronic Constipation |
|
|
| Completed | N/A | 100 | RoW | The combined seed extracts of Cassia obtusifolia Linne and Foeniculum vulgare Mill, Placebo group | Pusan National University Yangsan Hospital | Chronic Constipation | 12/23 | 12/23 | | |
NCT05729867: Efficacy and Safety of a Fully Covered Self-Expandable Metal Stent for Unresectable HCC |
|
|
| Recruiting | N/A | 50 | RoW | Endoscpic biliary drainage using fully covered metal stent | Seoul National University Hospital | Malignant Biliary Obstruction, Hepatocellular Carcinoma | 04/24 | 04/25 | | |
NCT06120348: Study of Application of Pulse Electrical Stimulation Around Eye in Dry Eye Disease Patients Who Are Scheduled for Laser Epithelial Keratomileusis (LASEK) Surgery |
|
|
| Recruiting | N/A | 178 | RoW | Charge-Balanced, Symmetric Nerve Stimulation, Sham Stimulation | Nu Eyne Co., Ltd. | Dry Eye Disease | 04/24 | 08/24 | | |
NCT06427083: Registry Study to Determine the Effectiveness and Safety of Weight Loss With Enavogliflozin in Patients With Type 2 Diabetes Mellitus |
|
|
| Recruiting | N/A | 240 | RoW | Envlo Tablet, Envolomet SR Tablet | Daewoong Pharmaceutical Co. LTD. | Type 2 Diabetes Mellitus | 12/25 | 06/26 | | |
NCT06419816: Effect of Linking Data Using Smartphone Application, 'Well Check', on Clinical Outcomes in Patients With Type 2 Diabetes Mellitus |
|
|
| Recruiting | N/A | 480 | RoW | Physician-managed "WellCheck" use, self-managed "WellCheck" use | Daewoong Pharmaceutical Co. LTD. | Type 2 Diabetes | 12/25 | 06/26 | | |
NCT06628804: Artemisia and Green Tea Extracts for Gastric Mucosal Health |
|
|
| Enrolling by invitation | N/A | 100 | RoW | Artemisia and green tea extracts, Placebo | Pusan National University Yangsan Hospital | Functional Dysphonia | 12/25 | 12/25 | | |
NCT06629805: β-glucan and Exercise on Musculoskeletal Function in Sarcopenic Adults |
|
|
| Enrolling by invitation | N/A | 116 | RoW | Aureobasidium pullulans produced β-glucan, Placebo | Pusan National University Yangsan Hospital | Sarcopenia | 12/25 | 12/25 | | |
NCT05493904: PREcise Percutaneous Coronary Intervention for Stent OptimizatION in Treatment of COMPLEX Lesion (PRECISION-COMPLEX) |
|
|
| Recruiting | N/A | 320 | RoW | OCT-guided PCI, Angiography-guided PCI, Drug-eluting stent | Chonnam National University Hospital, Abbott Medical Devices | Coronary Artery Disease, Angina Pectoris | 08/24 | 12/26 | | |
NCT05065125: Clinical Usefulness of Digital Single-operator Cholangioscopy(SpyGlassâ„¢) for Post-liver Transplant Anastomotic Stricture |
|
|
| Recruiting | N/A | 40 | RoW | digital single-operator cholangioscopy | Seoul National University Hospital | Liver Transplant; Complications, Biliary Duct Obstruction, Anastomosis, Obstructed | 09/24 | 12/24 | | |
NCT06630455: Meu-cinn for Gastric Mucosal Health in Adults With Functional Dyspepsia |
|
|
| Not yet recruiting | N/A | 100 | RoW | Meu-cinn, Placebo | Pusan National University Yangsan Hospital | Functioanl Dyspepsia | 12/25 | 12/25 | | |
NCT05596370: Association Between Cell-free Nucleic Acid in Blood, Urine and Microbiome in Stool With Pancreatobiliary Cancer |
|
|
| Recruiting | N/A | 150 | RoW | cell free DNA in blood and urine, metabolite/microbiome in urine and stool | Seoul National University Hospital, DXOME CO., LTD. | Pancreatic Cancer, Cholangiocarcinoma, Gallbladder Cancer | 12/24 | 12/24 | | |
NCT05497271: Confirmation of Association Between Cystic Fluid Analysis With Pancreatic Cystic Lesions |
|
|
| Recruiting | N/A | 500 | RoW | | Seoul National University Hospital | Pancreatic Cyst, Molecular, Chemical Analysis of Cystic Fluid | 12/25 | 12/25 | | |
ASSIST, NCT05529459: Anatomic Versus Physiologic Guidance for Complete Revascularization With DES Eluting in Patients With CAD |
|
|
| Recruiting | N/A | 2400 | RoW | Percutaneous Coronary Intervention | Seung-Whan Lee, M.D., Ph.D., Biotronik Korea Co., Ltd | Coronary Disease | 12/26 | 07/30 | | |
| Recruiting | N/A | 1350 | RoW | Percutaneous coronary intervention | Samsung Medical Center, Seoul St. Mary's Hospital, Seoul National University Bundang Hospital, Korea University Ansan Hospital, Chonnam National University Hospital, Chung-Ang University Gwangmyeong Hospital, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gyeongsang National University Hospital, Uijeongbu St. Mary Hospital, Keimyung University Dongsan Medical Center, Inha University Hospital, Chungbuk National University, Wonju Severance Christian Hospital, SMG-SNU Boramae Medical Center, Kangbuk Samsung Hospital, Sungkyunkwan University, Ewha Womans University, Korea University Guro Hospital | Coronary Artery Disease | 07/27 | 12/28 | | |
Symphony, NCT04912674: Evaluation of ™ Posterior Cervical System for Surgical Treatment of Adult Cervical Deformity |
|
|
| Recruiting | N/A | 100 | US | Symphony OCT System | International Spine Study Group Foundation, DePuy Synthes | Cervical Deformity | 07/27 | 07/27 | | |
NCT06013306: Long-Term Follow-up Study of Subjects With Knee Osteoarthritis Who Had Administered FURESTEM-OA Kit Inj. in K0701 Study |
|
|
| Not yet recruiting | N/A | 58 | NA | | Kang Stem Biotech Co., Ltd. | Knee Osteoarthritis | 11/29 | 12/30 | | |
PCD 2, NCT04194996: Radiographic and Clinical Evaluation of Surgical Treatment for Cervical Deformity: A Multi-Center Study 2.0 |
|
|
| Recruiting | N/A | 200 | US | Surgical intervention | International Spine Study Group Foundation, DePuy Synthes, Orthofix Inc. | Cervical Deformity | 12/32 | 07/33 | | |
INCS/INAH, NCT05708157: Concomitant Intranasal Antihistamine and Corticosteroid in Stepwise Treatment Strategy for Allergic Rhinitis |
|
|
| Recruiting | N/A | 240 | RoW | concomitant intranasal antihistamine and corticosteroid | Gachon University Gil Medical Center, Hallym University Kangnam Sacred Heart Hospital, Gangneung Asan Hospital, Bundang Jesaeng Hospital, Chung-Ang University Gwangmyeong Hospital, Hallym University Medical Center | Allergic Rhinitis | 02/24 | 02/24 | | |
NCT05604573: DNA Mutation Detection in Circulating Tumor DNA and Tissue by mmADPS for Pancreatic Cancer |
|
|
| Recruiting | N/A | 150 | RoW | cell free DNA in blood, genetic mutation in tissue | Seoul National University Hospital, GENECAST Co., Ltd. | Pancreatic Cancer | 12/24 | 12/24 | | |
| Lee, Eun Bong |
Aladdin, NCT04618640: To Evaluate the Immunogenicity and Safety of DTaP-IPV Vaccine Administered as a Boosting Dose to Healthy Children of 4-6 Years |
|
|
| Recruiting | 3 | 249 | RoW | DTaP-IPV combination vaccine | Boryung Biopharma Co., Ltd. | Diphtheria, Tetanus, Pertussis, Poliomyelitis | 12/20 | 07/21 | | |
| Recruiting | 3 | 40 | RoW | MTX | Seoul National University Hospital | Rheumatoid Arthritis | 12/22 | 12/22 | | |
| Active, not recruiting | 3 | 291 | Europe, Canada, Japan, US, RoW | Selpercatinib, LY3527723, LOXO-292, Cabozantinib, Vandetanib | Loxo Oncology, Inc., Eli Lilly and Company | Medullary Thyroid Cancer | 05/23 | 02/26 | | |
NCT05317858: Blood-brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets |
|
|
| Recruiting | 3 | 20 | Canada, US, RoW | Blood Brain Barrier Disruption - Oncology, Exablate BBBD, Pembrolizumab | InSightec | Brain Tumor | 06/24 | 12/24 | | |
NCT05757102: A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma |
|
|
| Recruiting | 3 | 292 | US, RoW | FF/UMEC/VI, ELLIPTA, FF/VI | GlaxoSmithKline | Asthma | 01/27 | 01/27 | | |
NCT06001606: Immunogenicity, Reactogenicity of Shingrix in SLE |
|
|
| Recruiting | 3 | 63 | RoW | Shingrix, Placebo | Seoul National University Hospital | Zoster, Systemic Lupus Erythematosus, Vaccine Reaction | 04/25 | 04/25 | | |
| Active, not recruiting | 3 | 597 | Europe, RoW | Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer | United Therapeutics | Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease | 07/25 | 07/25 | | |
SHINE-2, NCT05784246: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis |
|
|
| Recruiting | 3 | 60 | Europe, Canada, Japan, US, RoW | Mirikizumab IV, LY3074828, Mirikizumab SC | Eli Lilly and Company | Ulcerative Colitis | 07/26 | 03/27 | | |
OPTIMAL, NCT03315364: Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy |
|
|
| Active, not recruiting | 2/3 | 549 | Europe, RoW | Oral paclitaxel, Liporaxel®, Paclitaxel injection, Taxol® | Daehwa Pharmaceutical Co., Ltd. | Recurrent or Metastatic Breast Cancer | 02/24 | 12/25 | | |
NAVIGATE, NCT04365868: Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis |
|
|
| Active, not recruiting | 2b | 357 | Europe, Canada, US, RoW | belapectin, GR-MD-02, galactoarabino rhamnogalacturonate, Placebo | Galectin Therapeutics Inc. | Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis | 12/24 | 12/24 | | |
NCT05032066: A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis |
|
|
| Active, not recruiting | 2 | 153 | Europe, Canada, Japan, US, RoW | HZN-825, Placebo | Amgen | Idiopathic Pulmonary Fibrosis | 07/24 | 07/25 | | |
|
| Active, not recruiting | 2 | 103 | Europe, US, RoW | Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627 | Chinook Therapeutics, Inc. | IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease, Diabetic Nephropathy Type 2, Immunoglobulin A Nephropathy | 07/24 | 07/26 | | |
| Active, not recruiting | 2 | 532 | Europe, Japan, US, RoW | Enpatoran low dose, M5049, Enpatoran medium dose, Enpatoran high dose, Placebo | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Systemic Lupus Erythematosus | 11/24 | 12/24 | | |
|
| Active, not recruiting | 2 | 129 | Europe, US, RoW | BBT-877, Placebo | Bridge Biotherapeutics, Inc. | Idiopathic Pulmonary Fibrosis | 01/25 | 09/25 | | |
|
|
| Recruiting | 2 | 532 | Europe, Japan, US, RoW | M5049 low dose, Enpatoran, M5049 medium dose, M5049 high dose, Placebo, M5049 very high dose | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, Merck Healthcare KGaA | Systemic Lupus Erythematosus | 04/25 | 04/25 | | |
ECHO, NCT03062072: Emergence of Chemotherapy Related Hyperglycemia in nOn-diabetic Patients |
|
|
| Recruiting | N/A | 300 | RoW | Chemotherapy, cytotoxic chemotherapeutic agents | National Cancer Center, Korea, SMG-SNU Boramae Medical Center | Cancer, Colon Cancer, Breast Cancer, Malignant Lymphoma | 12/17 | 12/22 | | |
MUST-BE, NCT02909426: The Mammography and Ultrasonography STudy for Breast Cancer Screening Effectiveness |
|
|
| Active, not recruiting | N/A | 11880 | RoW | Ultrasonography, Digital mammography | Soonchunhyang University Hospital, Ministry of Health & Welfare, Korea | Invasive Cancer, Ductal Carcinoma in Situ | 12/20 | 12/23 | | |
| Completed | N/A | 39 | RoW | Vasopressin, Vasopressin 20U | Seoul National University Hospital, CHA University | Uterine Leiomyoma | 12/21 | 12/22 | | |
| Not yet recruiting | N/A | 499 | RoW | | National Cancer Center, Korea, Seoul National University Bundang Hospital, SMG-SNU Boramae Medical Center, Seoul National University Hospital | Thyroid Cancer, Papillary Thyroid Carcinoma | 12/29 | 12/32 | | |
| Recruiting | N/A | 10000 | RoW | Biologic or targeted synthetic DMARD, etanercept, adalimumab, infliximab, golimumab, tocilizumab, abatacept, rituximab, ustekinumab, secukinumab, ixekizumab, or biosimilars, tofacitinib, baricitinib, upadacitinib | Seoul National University Hospital | Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis | 12/29 | 06/30 | | |
NCT05848271: Natural History Study of Patients With HPDL Mutations |
|
|
| Recruiting | N/A | 50 | US | Patient Registry, Dry blood spots sampling | University of California, San Diego, New York University, Universität Tübingen, Heinrich-Heine University, Duesseldorf | Mitochondrial Encephalomyopathies, Hereditary Spastic Paraplegia, Spastic Paraplegia, White Matter Disease, Neonatal Encephalopathy, Mutation, Genetic Disease | 12/24 | 12/24 | | |
NCT05241041: Effects of Positive Psychological Group Psychotherapy and Auricular Acupressure on Withdrawal Symptoms |
|
|
| Recruiting | N/A | 240 | RoW | group counseling, auricular acupressure, placebo acupressure | Inha University Hospital, National Research Foundation of Korea | Gambling | 02/25 | 02/26 | | |
| Isambert, Nicolas |
| Active, not recruiting | 3 | 603 | Europe | Nilotinib, TASIGNA, Ceritinib, ZYKADIA, Capmatinib, Lapatinib, TYVERB, Trametinib, MEKINIST, Trametinib and Dabrafenib, MEKINIST and TAFINLAR, Olaparib and Durvalumab, LYNPARZA, MEDI4736, Palbociclib, IBRANCE, PD-0332991, Glasdegib, PF-04449913, TAS-120, Next Generation sequencing exome, RNA Seq, NGS, High throughput sequencing | Institut National de la Santé Et de la Recherche Médicale, France, Commissariat A L'energie Atomique, Institut Bergonié, Plateforme labellisée Inca - Institut Bergonié, Bordeaux, Plateforme labellisée Inca - Hôpital Européen Georges Pompidou, Paris, EUCLID Clinical Trial Platform | Soft Tissue Sarcoma | 12/23 | 10/25 | | |
CIRSARC, NCT03805022: Benefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue Sarcomas |
|
|
| Recruiting | 3 | 351 | Europe | Doxorubicin, Ifosfamide or dacarbazine, At the discretion of the investigator | Institut Bergonié, Novartis, Chugai Pharma France | Non-metastatic Soft-tissue Sarcoma, Resectable | 02/25 | 02/25 | | |
RAR-Immune, NCT04741438: Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype |
|
|
| Recruiting | 3 | 96 | Europe | Nivolumab and IPILIMUMAB, Pazopanib Oral Tablet [Votrient] | Centre Leon Berard | Sarcoma | 02/25 | 08/25 | | |
CHIC-STS01, NCT04307277: Interest of Peri Operative CHemotherapy In Patients With CINSARC High-risk Localized Soft Tissue Sarcoma |
|
|
| Recruiting | 3 | 600 | Europe | Standard of care + chemotherapy, Standard of care | Institut Claudius Regaud | Soft Tissue Sarcoma | 03/25 | 03/25 | | |
MOIO, NCT05078047: Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO |
|
|
| Recruiting | 3 | 646 | Europe | Reduced dose intensity of IO | UNICANCER | Lung Cancer Metastatic, Renal Cell Carcinoma, Head and Neck Cancer, Triple Negative Breast Cancer, Merkel Cell Carcinoma, Hepatocellular Carcinoma, Melanoma, Urothelial Carcinoma, Colorectal Carcinoma With Microsatellite Instability, Esophageal Squamous Cell Carcinoma, Endometrial Carcinoma, Cervical Cancer, Gastric/Gastro-esophageal Junction/Esophageal Adenocarcinoma, Basal Cell Carcinoma, Squamous Skin Carcinoma | 03/25 | 03/25 | | |
ELAINE 3, NCT05696626: Evaluation of Lasofoxifene Combined with Abemaciclib Compared with Fulvestrant Combined with Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 Mutation |
|
|
| Recruiting | 3 | 400 | Europe, Canada, US, RoW | Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib | Sermonix Pharmaceuticals Inc. | Metastatic Breast Cancer | 06/25 | 06/26 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
| Recruiting | 2 | 173 | Europe | Durvalumab, Tazemetostat | Institut Bergonié, AstraZeneca, Epizyme, Inc. | Advanced Solid Tumor, Advanced Colorectal Carcinoma, Advanced Soft-tissue Sarcoma, Advanced Pancreatic Adenocarcinoma, Adult Solid Tumor | 07/23 | 01/25 | | |
LENVAGIST, NCT04193553: Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure |
|
|
| Completed | 2 | 77 | Europe | Lenvatinib, Placebo, Best supportive care | Centre Leon Berard | Gastro Intestinal Stromal Tumour | 01/24 | 04/24 | | |
| Active, not recruiting | 2 | 127 | Europe | Regorafenib, stivarga, Placebo | Centre Oscar Lambret | Metastatic Soft Tissue Sarcoma | 03/24 | 03/25 | | |
CARMEN-LC05, NCT04524689 / 2020-000035-50: Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC |
|
|
| Active, not recruiting | 2 | 57 | Europe, US, RoW | SAR408701 (Tusamitamab ravtansine), Tusamitamab ravtansine, Pembrolizumab, Keytruda, Cisplatin, Carboplatin, Pemetrexed | Sanofi | Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC) | 03/24 | 12/24 | | |
|
AGADIR, NCT03915678: Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 2 | 247 | Europe | Association atezolizumab + BDB001 + RT, Association atezolizumab + BDB001+ RT | Institut Bergonié, Roche Pharma AG, National Cancer Institute, France, Eikon Therapeutics | Solid Tumor, Adult, Pancreatic Cancer, Virus-associated Tumors, Non Small Cell Lung Cancer, Melanoma, Bladder Cancer, Triple Negative Breast Cancer | 09/24 | 03/26 | | |
TRUST, NCT04874311: Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma |
|
|
| Recruiting | 2 | 80 | Europe | Bintrafusp alfa, Doxorubicin | Institut Bergonié, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma | 09/24 | 03/25 | | |
| Recruiting | 2 | 72 | Europe | Association of berzosertib with gemcitabine, Experimental, Gemcitabine, Control | Institut Bergonié, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Leiomyosarcoma, Adult | 10/24 | 04/26 | | |
L-UteCIN, NCT06524583: Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour |
|
|
| Not yet recruiting | 2 | 198 | Europe | Doxorubicin, Trabectedin, Yondelis | UNICANCER, PharmaMar, Ligue contre le cancer, France, National Research Agency, France, University Hospital, Marseille, Institut Claudius Regaud, Institut Bergonié, Oncopole | Leiomyosarcoma Uterus | 12/29 | 12/30 | | |
ATEZOGIST, NCT05152472: A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments |
|
|
| Recruiting | 2 | 110 | Europe | Atezolizumab 1200 mg, Tecentriq®, Imatinib 400 MG, Glivec® | Centre Leon Berard | Unresectable Gastrointestinal Stromal Tumor (GIST), Locally Advanced Gastrointestinal Stromal Tumor (GIST), Metastatic Gastrointestinal Stromal Tumor | 10/27 | 10/27 | | |
| Active, not recruiting | 2 | 256 | Europe, Canada, US, RoW | Avelumab, MSB0010718C, Sacituzumab Govitecan, IMMU-132, Trodelvy™, GS-0132, M6223, NKTR-255 | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics | Locally Advanced or Metastatic Urothelial Carcinoma | 01/25 | 01/25 | | |
Decrescendo, NCT04675827: De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade |
|
|
| Suspended | 2 | 1065 | Europe, RoW | Pertuzumab and tratuzumab fixed dose combination, Adjuvant pertuzumab + trastuzumab FDC SC for 14 cycles, Fixed-dose combination of Perjeta and Herceptin for subcutaneous injection for 14 cycles, Trastuzumab emtansine, Adjuvant T-DM1 | Jules Bordet Institute, Breast International Group, Hoffmann-La Roche, International Drug Development Institute, Institut Curie | HER2-positive Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer, Node-negative Breast Cancer | 06/27 | 03/29 | | |
RIBOLARIS, NCT05296746: Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer |
|
|
| Recruiting | 2 | 1100 | Europe | Ribociclib (neoadjuvant), Kisqali, Chemotherapy (adjuvant), Ribociclib (adjuvant) | SOLTI Breast Cancer Research Group, Novartis, UNICANCER | Breast Cancer Stage II | 08/28 | 07/30 | | |
METex14, NCT04868877 / 2021-000203-20: Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination |
|
|
| Recruiting | 1/2 | 576 | Europe, US, RoW | MCLA-129, bispecific, Osimertinib, Tagrisso, Chemotherapy | Merus N.V. | Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer | 03/26 | 03/27 | | |
OMNIA-1, NCT05578872: A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (). |
|
|
| Recruiting | 1/2 | 130 | Europe, US | ANV419, Pembrolizumab, Ipilimumab | Anaveon AG | Melanoma (Skin), Cutaneous Melanoma, Adult Disease, Advanced Solid Tumor, Metastatic Melanoma | 09/24 | 12/24 | | |
ELECTRA, NCT05386108: Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to ER+/HER-2- Breast Cancer |
|
|
| Recruiting | 1/2 | 68 | Europe, US, RoW | Elacestrant, Elacestrant dihydrochloride, RAD-1901, ER-306323, Orserdu, Abemaciclib, Verzenio | Stemline Therapeutics, Inc. | Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Central Nervous System Neoplasms, Brain Diseases, Central Nervous System Diseases | 12/25 | 12/25 | | |
| Recruiting | 1/2 | 500 | Europe, Canada, Japan, US, RoW | Oral repotrectinib (TPX-0005), repotrectinib | Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd. | Locally Advanced Solid Tumors, Metastatic Solid Tumors | 02/28 | 02/28 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Recruiting | 1 | 255 | Europe, US, RoW | ELVN-002, Trastuzumab, 5-Fluorouracil, Oxaliplatin, Capecitabine, Eribulin, paclitaxel, Leucovorin | Enliven Therapeutics | HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors, HER2 Amplification, Colorectal Cancer | 01/27 | 07/28 | | |
